Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1989 Dec;57(12):3778–3782. doi: 10.1128/iai.57.12.3778-3782.1989

Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate.

P Domenico 1, S Schwartz 1, B A Cunha 1
PMCID: PMC259904  PMID: 2680983

Abstract

Heavily encapsulated Klebsiella pneumoniae (serotypes 1 and 2) was cultured in the presence of sodium salicylate. The addition of salicylate (2 to 30 micrograms/ml) progressively decreased the amount of capsular polysaccharide produced by all strains without significantly inhibiting cell growth. Further addition of salicylate (50 to 200 micrograms/ml) was progressively inhibitory to cell growth and decreased the production of polysaccharide only slightly. The optimal concentration of salicylate that could reduce the polysaccharide production of heavily encapsulated, virulent strains by 50% or more was 30 micrograms/ml. Mutants of these bacteria that produced less capsule were affected by salicylate to a lesser degree. All concentrations of salicylate tested were physiologically achievable in humans and within the therapeutic range of aspirin. The addition of calcium and magnesium partially reversed the effects of salicylate on polysaccharide production. Chelating agents, particularly EGTA [ethylene-bis(oxyethylenenitrile)tetraacetic acid], reduce capsule production as salicylate did. Thus, the chelation of calcium and magnesium by salicylate could account, at least in part, for the reduction of capsule. Optical density measurements allowed for rapid monitoring of capsule production in various culture media because a large part of culture turbidity was apparently due to the capsule. Decreased production of the primary K. pneumoniae virulence factor with salicylate may have therapeutic potential.

Full text

PDF
3778

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amako K., Meno Y., Takade A. Fine structures of the capsules of Klebsiella pneumoniae and Escherichia coli K1. J Bacteriol. 1988 Oct;170(10):4960–4962. doi: 10.1128/jb.170.10.4960-4962.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BAER H., EHRENWORTH L. The pathogenicity of Klebsiella pneumoniae for mice: the relationship to the quantity and rate of production of type-specific capsular polysaccharide. J Bacteriol. 1956 Nov;72(5):713–717. doi: 10.1128/jb.72.5.713-717.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BATSHON B. A., BAER H., SHAFFER M. F. Immunologic paralysis produced in mice by Klebsiella pneumoniae type 2 polysaccharide. J Immunol. 1963 Jan;90:121–126. [PubMed] [Google Scholar]
  4. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem. 1973 Aug;54(2):484–489. doi: 10.1016/0003-2697(73)90377-1. [DOI] [PubMed] [Google Scholar]
  5. Cohen J., McConnell J. S. Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin B. Eur J Clin Microbiol. 1986 Feb;5(1):13–17. doi: 10.1007/BF02013454. [DOI] [PubMed] [Google Scholar]
  6. Costerton J. W. The etiology and persistence of cryptic bacterial infections: a hypothesis. Rev Infect Dis. 1984 Sep-Oct;6 (Suppl 3):S608–S616. doi: 10.1093/clinids/6.supplement_3.s608. [DOI] [PubMed] [Google Scholar]
  7. DUGUID J. P., WILKINSON J. F. The influence of cultural conditions on polysaccharide production by Aerobacter aerogenes. J Gen Microbiol. 1953 Oct;9(2):174–189. doi: 10.1099/00221287-9-2-174. [DOI] [PubMed] [Google Scholar]
  8. Dalhoff A., Stübner G. Comparative analysis of the antimicrobial action of polymorphonuclear leucocytes in vitro, ex vivo and in vivo. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):283–291. doi: 10.1093/jac/15.suppl_a.283. [DOI] [PubMed] [Google Scholar]
  9. Domenico P., Diedrich D. L., Straus D. C. Extracellular polysaccharide production by Klebsiella pneumoniae and its relationship to virulence. Can J Microbiol. 1985 May;31(5):472–478. doi: 10.1139/m85-088. [DOI] [PubMed] [Google Scholar]
  10. Domenico P., Johanson W. G., Jr, Straus D. C. Lobar pneumonia in rats produced by clinical isolates of Klebsiella pneumoniae. Infect Immun. 1982 Jul;37(1):327–335. doi: 10.1128/iai.37.1.327-335.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Foulds J., Murray D. M., Chai T., Rosner J. L. Decreased permeation of cephalosporins through the outer membrane of Escherichia coli grown in salicylates. Antimicrob Agents Chemother. 1989 Apr;33(4):412–417. doi: 10.1128/aac.33.4.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kadurugamuwa J. L., Anwar H., Brown M. R., Zak O. Effect of subinhibitory concentrations of cephalosporins on surface properties and siderophore production in iron-depleted Klebsiella pneumoniae. Antimicrob Agents Chemother. 1985 Feb;27(2):220–223. doi: 10.1128/aac.27.2.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Karkhanis Y. D., Zeltner J. Y., Jackson J. J., Carlo D. J. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem. 1978 Apr;85(2):595–601. doi: 10.1016/0003-2697(78)90260-9. [DOI] [PubMed] [Google Scholar]
  14. Kwong T. C. Salicylate measurement: clinical usefulness and methodology. Crit Rev Clin Lab Sci. 1987;25(2):137–159. doi: 10.3109/10408368709105880. [DOI] [PubMed] [Google Scholar]
  15. McLaughlin S. Salicylates and phospholipid bilayer membranes. Nature. 1973 May 25;243(5404):234–236. doi: 10.1038/243234a0. [DOI] [PubMed] [Google Scholar]
  16. Mizuta K., Ohta M., Mori M., Hasegawa T., Nakashima I., Kato N. Virulence for mice of Klebsiella strains belonging to the O1 group: relationship to their capsular (K) types. Infect Immun. 1983 Apr;40(1):56–61. doi: 10.1128/iai.40.1.56-61.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nassif X., Fournier J. M., Arondel J., Sansonetti P. J. Mucoid phenotype of Klebsiella pneumoniae is a plasmid-encoded virulence factor. Infect Immun. 1989 Feb;57(2):546–552. doi: 10.1128/iai.57.2.546-552.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pollack M. Significance of circulating capsular antigen in Klebsiella infections. Infect Immun. 1976 Jun;13(6):1543–1548. doi: 10.1128/iai.13.6.1543-1548.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rosner J. L. Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8771–8774. doi: 10.1073/pnas.82.24.8771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Simoons-Smit A. M., Verweij-van Vught A. M., MacLaren D. M. The role of K antigens as virulence factors in Klebsiella. J Med Microbiol. 1986 Mar;21(2):133–137. doi: 10.1099/00222615-21-2-133. [DOI] [PubMed] [Google Scholar]
  21. Straus D. C. Production of an extracellular toxic complex by various strains of Klebsiella pneumoniae. Infect Immun. 1987 Jan;55(1):44–48. doi: 10.1128/iai.55.1.44-48.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Williams P., Lambert P. A., Haigh C. G., Brown M. R. The influence of the O and K antigens of Klebsiella aerogenes on surface hydrophobicity and susceptibility to phagocytosis and antimicrobial agents. J Med Microbiol. 1986 Mar;21(2):125–132. doi: 10.1099/00222615-21-2-125. [DOI] [PubMed] [Google Scholar]
  23. Yokochi T., Nakashima I., Kato N. Effect of capsular polysaccharide of Klebsiella pneumoniae on the differentiation and functional capacity of macrophages cultured in vitro. Microbiol Immunol. 1977 Oct 20;21(10):601–610. doi: 10.1111/j.1348-0421.1977.tb00328.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES